GRK2抗体

+ +

•  

   

     Red: Control Antigen (100ng); Purple: Antigen (10ng); Green: Antigen (50ng); Blue: Antigen (100ng);    

  
  

•  

   

     Western blot analysis using GRK2 mouse mAb against Hela (1), Jurkat (2), MOLT4 (3), RAJI (4), THP-1 (5), L1210 (6), Cos7 (7), PC-12 (8), and NIH/3T3 (9) cell lysate.    

  
  

•  

   

     Immunofluorescence analysis of NIH/3T3 cells using GRK2 mouse mAb (green). Blue: DRAQ5 fluorescent DNA dye.    

  
  

•  

   

     Immunohistochemical analysis of paraffin-embedded human endometrial cancer tissues (left) and cervical cancer tissues (right) using GRK2 mouse mAb with DAB staining.    

  
  

The G Protein-Coupled Receptor Kinase 2 (GRK2) antibody is a crucial tool for studying the regulation of G protein-coupled receptor (GPCR) signaling pathways. GRK2. a member of the GRK family, phosphorylates activated GPCRs, promoting their desensitization and internalization to modulate cellular responses. It plays a pivotal role in cardiovascular, neurological, and immune systems by fine-tuning receptor signaling. Dysregulation of GRK2 is linked to pathological conditions, including heart failure, hypertension, inflammation, and cancer, making it a therapeutic target of interest.

GRK2 antibodies are widely used in research to detect expression levels, localization, and activity of GRK2 in tissues or cells. They enable techniques like Western blotting, immunohistochemistry, and flow cytometry, aiding in the exploration of GRK2's role in disease mechanisms. For example, elevated GRK2 levels in heart failure models correlate with impaired β-adrenergic signaling, while its downregulation in cancer may influence tumor progression. These antibodies also help assess the efficacy of GRK2 inhibitors in preclinical studies.

Developed against specific epitopes (e.g., N-terminal or catalytic domains), GRK2 antibodies vary in species reactivity (human, mouse, rat) and application compatibility. Validation ensures specificity to avoid cross-reactivity with homologous kinases like GRK3. As GRK2 emerges as a biomarker and therapeutic target, its antibodies remain vital for advancing mechanistic insights and translational research.